Our top pick for
Sonoma Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Sonoma Pharmaceuticals shares (SNOA) are listed on the NASDAQ and all prices are listed in US Dollars. Sonoma Pharmaceuticals employs 19 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$4.60 - $10.09|
|50-day moving average||$7.74|
|200-day moving average||$7.89|
|Wall St. target price||$9.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-7.06|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$21.8 million|
|Gross profit TTM||$8.3 million|
|Return on assets TTM||-11.3%|
|Return on equity TTM||-19.6%|
|Market capitalisation||$16.5 million|
TTM: trailing 12 months
There are currently 20,645 Sonoma Pharmaceuticals shares held short by investors – that's known as Sonoma Pharmaceuticals's "short interest". This figure is 1749.9% up from 1,116 last month.
There are a few different ways that this level of interest in shorting Sonoma Pharmaceuticals shares can be evaluated.
Sonoma Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Sonoma Pharmaceuticals shares currently shorted divided by the average quantity of Sonoma Pharmaceuticals shares traded daily (recently around 42132.653061224). Sonoma Pharmaceuticals's SIR currently stands at 0.49. In other words for every 100,000 Sonoma Pharmaceuticals shares traded daily on the market, roughly 490 shares are currently held short.
However Sonoma Pharmaceuticals's short interest can also be evaluated against the total number of Sonoma Pharmaceuticals shares, or, against the total number of tradable Sonoma Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sonoma Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Sonoma Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.01% of the tradable shares (for every 100,000 tradable Sonoma Pharmaceuticals shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sonoma Pharmaceuticals.
Find out more about how you can short Sonoma Pharmaceuticals stock.
We're not expecting Sonoma Pharmaceuticals to pay a dividend over the next 12 months.
Sonoma Pharmaceuticals's shares were split on a 1:9 basis on 19 June 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonoma Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Sonoma Pharmaceuticals shares which in turn could have impacted Sonoma Pharmaceuticals's share price.
Over the last 12 months, Sonoma Pharmaceuticals's shares have ranged in value from as little as $4.6 up to $10.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sonoma Pharmaceuticals's is 0.7976. This would suggest that Sonoma Pharmaceuticals's shares are less volatile than average (for this exchange).
Sonoma Pharmaceuticals, Inc. , develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.